# Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Source: https://onco.cc/trials/nct02786485/  
OnCo record `nct02786485` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, withdrawn before enrolling.

## Summary

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT is a phase 1 interventional study registered as NCT02786485 by Bellicum Pharmaceuticals, started 2016-05. Conditions recorded: Leukemia, Myelodysplastic Syndromes, Lymphomas, Multiple Myeloma and Other High-risk Hematological Malignancies. Interventions recorded: rivogenlecleucel and Rimiducid.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02786485
- Phase: 1
- Setting: A Phase I Study of Matched Unrelated Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
- Sponsor: Bellicum Pharmaceuticals

## Sources

- ClinicalTrials.gov NCT02786485: https://clinicaltrials.gov/study/NCT02786485

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Rivogenlecleucel](https://onco.cc/drugs/rivogenlecleucel/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/)

---
JSON: https://onco.cc/api/v1/entities/nct02786485.json